Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Capricor Therapeutics
company
About
Capricor Therapeutics is a biotechnology company focusing on cell and exosome-based therapeutics.
- 11 - 50
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $4.20M
- Industries
- Biotechnology,Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2005
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Capricor Therapeutics is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of cell and exosome-based therapeutics for the treatment and prevention of diseases. Its CAP-1002 is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19. The company was founded in 2005 and is headquartered in Los Angeles, California.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$14.20M
Capricor Therapeutics has raised a total of
$14.20M
in funding over 2 rounds. Their latest funding was raised on
Oct 20, 2016 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 20, 2016 | Grant | $4.20M | 1 |
National Institutes of Health
|
— | Detail |
| Feb 3, 2015 | Post-IPO Equity | $10M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Capricor Therapeutics is funded by 2 investors.
National Institutes of Health
and CureDuchenne Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
CureDuchenne Ventures
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
